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Summary morphology (Hardie 1989; Brin 1993). Acanthocytosis
was derived from the Greek ‘‘akantha,’’ or thorn, and
Chorea-acanthocytosis (CHAC) is a rare autosomal re-
is used to describe the spiky appearance of erythrocytes
cessive disorder characterized by progressive neurode-
occurring at elevated levels, in affected individuals. Thegeneration and unusual red-cell morphology (acantho-
signiﬁcance of abnormal red cells in a neurological con-cytosis), with onset in the third to ﬁfth decade of life.
text is unclear, as are the molecular events required forNeurological impairment with acanthocytosis (neuro-
acanthocyte formation. However, alterations in mem-acanthocytosis) also is seen in abetalipoproteinemia and
brane lipids and cytoskeletal proteins have been impli-X-linked McLeod syndrome. Whereas the molecular eti-
cated (Sakai et al. 1991). Bassen and Kornzweig (1950)ology of McLeod syndrome has been deﬁned (Ho et al.
ﬁrst associated acanthocytosis with neurological abnor-1994), that of CHAC is still unknown. In the absence of
malities when they described the rare, autosomal reces-cytogenetic rearrangements, we initiated a genomewide
sive syndrome abetalipoproteinemia. A defect in lipid-scan for linkage in 11 families, segregating for CHAC,
loading of apolipoprotein B initiates a series of eventswho are of diverse geographical origin. We report here
leading to fat intolerance and fat-soluble vitamin deﬁ-that the disease is linked, in all families, to a 6-cM region
ciency (Narcisi et al. 1995).of chromosome 9q21 that is ﬂanked by the recombinant
McLeod syndrome is an X-linked disorder character-markers GATA89a11 and D9S1843. A maximum two-
ized by weak expression of Kell blood-group antigenspoint LOD score of 7.1 (u Å .00) for D9S1867 was
(Marsh 1983; Redman and Marsh 1993). The XK gene,achieved, and the linked region has been conﬁrmed by
disrupted in this condition, codes for a novel proteinhomozygosity-by-descent, in offspring from inbred fam-
with structural features characteristic of prokaryotic andilies. These ﬁndings provide strong evidence for the
eukaryotic membrane-transport proteins (Ho et al.involvement of a single locus for CHAC and are the ﬁrst
1994). Its exact role in the pathogenesis of neurologicalstep in positional cloning of the disease gene.
symptoms (Witt et al. 1992) is still unknown.
CHAC, like McLeod syndrome, is characterized by
Introduction involuntary movements and progressive neurodegenera-
tion (Hardie et al. 1991; Brin 1993). Chorea, which isChorea-acanthocytosis (CHAC) is a rare autosomal re-
the most characteristic associated movement abnormal-cessive disorder that is described, with at least two other
ity, is deﬁned as random, abrupt, irregular involuntarysyndromes, as ‘‘neuroacanthocytosis’’ (Hardie 1989;
movements of variable severity. In most cases, symptomBrin 1993). The core symptoms of the neurological syn-
onset is delayed until 25–45 years of age. Motor ordromes that comprise neuroacanthocytosis are difﬁcult
vocal tics also are observed in CHAC, as are dystonia,to distinguish clinically and occur with aberrant red-cell
Parkinsonism, progressive supranuclear palsy, and
apraxia of the eyelid opening (Jankovic 1986; Peppard
et al. 1990; Hardie et al. 1991; Brin 1993). DegenerationReceived June 11, 1997; accepted for publication July 31, 1997.
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noia, and/or personality change and even may lead to symptoms (listed above) seen in affected individuals var-
ied signiﬁcantly (see Hardie et al. 1991) but, when con-suicide (Aguilar i Bascompte et al. 1988; Alonso et al.
1989; Kartsounis and Hardie 1996). Chorea, orofacial sidered together with the molecular and biochemical in-
formation, were deemed sufﬁcient for a correctdyskinesia, and epileptic seizures underlie the commonly
found tongue and lip biting (Hardie et al. 1991; diagnosis.
Schwartz et al. 1992). An axonal neuropathy leading to
CHAC Familiesthe depression of reﬂexes and muscle atrophy is shared
by both CHAC andMcLeod syndrome (Kito et al. 1980; Family CHAC1.—This family, from the United
Kingdom, was ascertained by Hardie et al. and wasHardie et al. 1991;Witt et al. 1992). There is no effective
long-term treatment for either condition. Verapamil has termed ‘‘family H’’ in their original report (Hardie et
al. 1991; Kartsounis and Hardie 1996). Two affectedbeen found to be of only temporary help (Brenes et al.
1990). females (individuals II-8 and II-9) and 12 unaffected
relatives (individuals II-4, II-5, II-6, II-7, III-1, III-2, III-Genetic heterogeneity appeared to be a feature of
CHAC, since both autosomal dominant (Levine et al. 4, III-5, III-6, III-7, III-8, and III-10) were available for
study (see Hardie et al. 1991).1968) and recessive (Vance et al. 1987) transmission
have been reported. However, an autosomal recessive Family CHAC2.—Originally from France, this family
is the result of a consanguineous marriage between sec-mode of transmission seemed most likely, given that a
number of studies have reported the disease in inbred ond cousins. Seven unaffected and two affected mem-
bers were available for study (ﬁg. 1). Individual IV-5families (Bird et al. 1978; Alonso et al. 1989). Clinical
studies have used a variety of different terms for what had been studied previously (Ferrer et al. 1990).
Family CHAC3.—From Italy, this family had two af-was quite likely the same disorder—for example, ‘‘fa-
milial amyotrophic chorea with acanthocytosis,’’ fected brothers, who died at 29 and at 37 years of age.
The latter individual and four unaffected members of‘‘CHAC,’’ and ‘‘Levine-Critchley syndrome’’ (Kito et al.
1980; Sakai et al. 1985). It also is likely that disease his family were available for study. The proband had
been reported in a previous study (case 2 in Malandriniprevalence has been underestimated because the disease
can be mistaken easily for Huntington disease or may et al. 1993).
Family CHAC4.—This family, from the United States,have been diagnosed as so-called subchorea or atypical
chorea (Lange et al. 1976; Serra et al. 1986; Vance et provided one affected individual and 13 unaffected indi-
viduals, from three generations, for analysis.al. 1987; Alonso et al. 1989; Brin 1993).
We performed linkage studies on 11 families, segre- Family CHAC5.—From the United States, this family
provided an affected brother and sister, an unaffectedgating for CHAC, who are of diverse geographical ori-
gin. The results of these studies were conﬁrmed, by ho- sister, and both parents for study (family A in Vance et
al. 1987; case 1 in Kaplan et al. 1986).mozygosity-by-descent (HBD) analysis, in offspring
from consanguineous marriages and, together, provide Family CHAC6.—From this family of Turkish origin,
both parents, one affected sib, and three unaffected sibsstrong evidence for the CHAC gene being located on
chromosome 9q21. were studied. Individual II-4 (born in 1978) was re-
corded as ‘‘phenotype unknown,’’ for linkage analysis
(ﬁg. 1).Subjects and Methods
Family CHAC7.—A Mexican family of an unknown
degree of consanguinity had given rise to a sibship withThe clinical features of the neuroacanthocytosis syn-
dromes are very similar. In order to reduce the risk of ﬁve affected and four unaffected individuals. Three of
the affected individuals, who were unavailable for ge-misdiagnosis, a protocol was designed for ascertainment
of putative CHAC families, at the clinical, biochemical, netic analysis, had been studied elsewhere (Alonso et al.
1989).and molecular levels. CHAC was diagnosed if a neuro-
logical syndrome was associated with acanthocytosis Family CHAC8.—An Italian family, derived from a
ﬁrst-cousin marriage, had one affected and three unaf-and if abetalipoproteinemia and McLeod syndrome
were excluded through assessment of blood lipids or fected individuals available for study.
Family CHAC9.—From the United Kingdom, bothlipoproteins, as well as through Kell blood-group typing
or mutation analysis of the XK gene (Ho et al. 1994). parents and both affected sibs were tested (family B in
Hardie et al. 1991; also see Kartsounis and HardieThe neurological syndrome could consist of move-
ment disorders (chorea, tics, vocalizations, tongue/lip 1996). Interestingly, the male and female sibs developed
symptoms at 8 and 12 years of age, respectively.biting, dystonia, or Parkinsonism), caudate-nucleus at-
rophy, myopathy, neuropathy, epilepsy, or abnormali- Family CHAC10.—From this Italian family, one par-
ent, one affected sib, and four unaffected sibs were stud-ties in the neuropsychological or psychopathological ex-
amination. The severity and number of neurological ied.
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Family CHAC11.—From this English family, both order, proximal to distal): D9S147E, D9S15, and
D9S175 (Reed et al. 1994); D9S1844, D9S1837,parents, one affected sib, and one unaffected sib were
available for study. D9S175, D9S1860, D9S1807, D9S1834, D9S1674,
D9S153, D9S1780, D9S1785, D9S1867, D9S1843,
Isolated Cases D9S167, and D9S152 (Dib et al. 1996); and
AFM207vb8, AFMa101xd1, AFMb358xe9, andDNA from 13 affected individuals, received without
data from relatives or as data from single-child families AFM273vb1, which are genetically unmapped Ge´n-
e´thon CA-repeat markers that have been mapped onto(with data from both parents, which was uninformative
for linkage analysis), was tested for HBD across the the Whitehead Institute/CEPH mega-YAC maps. The
following tetranucleotide-repeat markers from the Co-linked region. Cases 13, 16, 18, and 19 from the study
by Hardie et al. (1991) (also see Kartsounis and Hardie operative Human Linkage Center were chosen ac-
cording to their location as deﬁned by the Whitehead1996) and nine other cases were studied.
Institute/CEPH mega-YAC maps: GATA89a11, GGAT-
Genotyping 13b07, GATA89c08, GATA21f05, and GATA3d04
(Shefﬁeld et al. 1995). Haplotypes were constructedDNA from available family members was isolated
from fresh blood samples or from permanent B-lympho- manually by use of the 15 most informative markers, by
minimization of recombination events between markers,cyte cell lines, by use of a NucleonTM Biosciences DNA-
extraction kit. A panel of 280 microsatellite markers and were conﬁrmed by use of SIMWALK2 (Sobel and
Lange 1996).for ﬂuorescence-based detection were selected for the
genome scan (Reed et al. 1994). PCR reactions were
performed in 96-well Costar (ThermowellTM) plates in Results
a 15-ml volume, on 40 ng of genomic DNA, with MJ
Two-Point Evidence for Linkage to Chromosome 9q21225 PCR machines. Products were detected with a
model 373A DNA sequencer (Applied Biosystems), and A genomewide search for linkage was initiated for 11
data were analyzed by use of GenescanTM (version 2.0.2) families, after power calculations indicated a statistically
and GenotyperTM (version 1.1). signiﬁcant likelihood of detection of linkage, given the
density of the markers to be used and the families avail-
Linkage Analysis able for study (ﬁg. 1). Two-point LOD scores were gen-
Data was analyzed under the assumption that erated for 70 markers corresponding to various chromo-
CHAC is a fully penetrant, autosomal recessive disor- somes, before a two-point LOD scoreú1 was calculated
der. In the absence of any published estimates of the for D9S15 (1.81 at u Å .00; table 1), which is tightly
prevalence of CHAC, in the general population, a dis- linked to the Friedreich ataxia locus (FRDA) at 9q13-
ease-gene frequency of .003 (Ç1/100,000) was esti- q21 (Fujita et al. 1990). Flanking markers D9S147e and
mated. Because of the potential for age-dependent D9S175, which were in the genome-scan set, gave LOD
penetrance, unaffected individuals under the age of scores of .90 (u Å .20) and 2.70 (u Å .05), respectively
25 years were considered to be ‘‘phenotype un- (table 1). Since D9S167, which is 14 cM distal to
known,’’ for linkage analysis. Power calculations were D9S175 (Dib et al. 1996), achieved a LOD score of 2.74
performed by use of SLINK (Weeks et al. 1990). Geno- (u Å .05), the region between D9S175 and D9S167 was
typing data was converted to LINKAGE format by studied in the CHAC families with a greater marker
use of the GAS package (version 2.0) (1993–1995 density (table 1 and ﬁg. 2).
by Alan Young, Oxford University), and inbreeding
Haplotype Analysis and Fine Mappingloops were broken by use of MAKEPED, in order to
perform the linkage analysis using MLINK from the Cumulative two-point LOD scores for the most infor-
mative markers tested are shown in table 1. HaplotypeLINKAGE package (Lathrop et al. 1984). Heterogene-
ity was assessed by use of the HOMOG program (ver- analysis indicated that CHAC is linked, in all families,
to this region of chromosome 9 and that no unaffectedsion 3.3) (Ott 1991), and multipoint linkage analysis
was performed by use of LINKMAP (Lathrop et al. members received the disease haplotype on both chro-
mosomes (table 1 and ﬁg. 1). Correspondingly, homoge-1985). No sex difference was assumed, and the exis-
tence of phenocopies could not be ruled out. neity was not rejected in a HOMOG test (data not
shown). The markers (cen-qter) GATA89c08, D9S1674,
Fine Mapping and Haplotyping D9S153, D9SS1780, D9S1867, and GATA21f05 were
nonrecombinant and deﬁned a critical region of 6 cMIn total, 26 polymorphic microsatellite markers were
used for the ﬁne mapping of chromosome 9q. The fol- for the CHAC disease locus (ﬁg. 1, ﬁg. 2, and table
1). The proximal recombination event was observed inlowing dinucleotide-repeat markers were obtained from
a number of sources (markers are listed in chromosomal affected individual CHAC2 IV-7, positioning the CHAC
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Figure 1 Haplotype analysis of 11 CHAC families. CHAC family members were analyzed for 15 polymorphic marker loci from chromo-
some 9q. The order of these genetic markers reﬂects their order, proximal (top nos.) to distal (bottom nos.), on chromosome 9 (based on Dib
et al. 1996 and the Whitehead Institute/CEPH mega-YAC maps). The disease-associated haplotype is indicated by boldface type in the darker-
shaded boxes. Haplotypes were assigned minimizing numbers of crossover events in each family. Proximal and distal recombination events
that deﬁne the critical region for the CHAC disease locus have occurred in affected individuals CHAC2 IV-7 and CHAC7 II-3, respectively.
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These recombination events identiﬁed GATA89c08, D9S1674, D9S153, D9S1780, D9S1867, and GATA21f05 as nonrecombinant markers.
Close scrutiny of the maternal haplotype for individual CHAC7 II-3 revealed that phase cannot be assigned for GATA21f05. This implies that
a recombination event may have occurred proximal to GATA21f05 (between GATA21f05 and D9S1867), which would exclude it from the
CHAC critical region. Light shading indicates markers for which phase cannot be assigned.
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Table 1
Cumulative Two-Point LOD Scores between the CHAC Locus and Chromosome 9q Markers
LOD SCORE AT u Å
MARKER .00 .01 .05 .10 .20 .30 .40
D9S147e 0 02.94 0.12 .72 .90 .55 .16
D9S15 0 0.64 1.40 1.81 1.49 .82 .23
D9S175 0 2.00 2.70 2.46 1.57 .75 .21
D9S1860 0 1.78 2.04 1.80 1.09 .49 .13
GATA89a11 0 2.29 2.56 2.33 1.59 .82 .24
GATA89c08 5.67 5.50 4.81 3.98 2.44 1.19 .36
D9S1674 6.57 6.36 5.55 4.56 2.74 1.28 .35
D9S153 4.46 4.32 3.77 3.08 1.84 .84 .22
D9S1780 6.25 6.06 5.33 4.43 2.74 1.33 .38
D9S1867 7.01 6.81 6.00 5.01 3.12 1.52 .42
GATA21f05 4.84 4.94 4.64 3.96 2.48 1.19 .32
D9S1843 0 4.44 4.92 4.40 2.88 1.45 .42
GATA3d04 0 3.46 3.81 3.41 2.20 1.05 .28
D9S167 0 2.24 2.73 2.50 1.62 .75 .19
D9S152 0 0.40 .97 1.24 .99 .52 .15
locus telomeric to GATA89a11 (table 2 and ﬁg. 1). The can be excluded from the CHAC critical region (table
3 and ﬁg. 2). Conventional haplotype analysis was un-distal recombination event in CHAC7 II-3 positioned
the CHAC locus centromeric to D9S1843. able to conclusively exclude or include GATA21f05 in
the critical region, since phase could not be assigned forHBD has provided strong evidence that GATA21f05
this marker, owing to maternal homozygosity in family
CHAC7 (ﬁg. 1). Haplotype analysis of offspring from a
consanguineous marriage (CHAC2 IV-5 and CHAC2
IV-7) suggested that ancestral recombination events
have occurred, thereby excluding this marker from the
CHAC disease region, owing to loss of HBD in both
individuals (table 3).
The highest two-point LOD score was 7.01 at uÅ .00,
for D9S1867 (table 1). Multipoint analysis across the
disease region, with the 15 polymorphic microsatellites,
conﬁrmed the critical region for CHAC and yielded a
multipoint LOD score of 8.53, for D9S1867 (data not
shown).
Discussion
We have found linkage of CHAC to a 6-cM region
on chromosome 9q21, in 11 families of distinct geo-
graphical origin. These results indicate that the affected
family members suffer from a homogeneous, autosomal
recessive disorder.
It is widely recognized that rare recessive traits occur
more frequently in offspring of consanguineous mar-
riages than in the general population (Lander and
Botstein 1987; Farrall 1993). Homozygosity mapping
relies on the use of multipoint linkage analysis to identify
Figure 2 Genetic map of chromosome 9q21, showing the CHAC HBD regions shared by inbred affected children and
critical region. Genetic distances between adjacent markers are sex-aver-
inherited from a recent ancestor common to both theaged recombination fractions, in centimorgans (cM). The order of and
maternal and paternal lineages (Lander and Botsteindistances between markers are based on data from a number of sources
(Dib et al. 1996 and the Whitehead Institute/CEPH mega-YAC maps). 1987; Farrall 1993).
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Table 2
Two-Point LOD Scores between the CHAC Locus and Three Chromosome 9q Marker Loci,
for the 11 CHAC Families
LOD SCORE AT u Å
MARKER AND
CHAC FAMILY .00 .01 .05 .10 .20 .30 .40
GATA89a11:
1 1.16 1.14 1.02 .88 .58 .30 .08
2 0 01.40 0.73 0.46 0.21 0.08 0.01
3 .37 .37 .33 .28 .19 .10 .03
4 0.15 0.15 0.12 0.10 0.05 0.02 0.01
5 .73 .71 .62 .51 .31 .14 .03
6 0.05 0.05 0.04 0.03 0.02 0.01 0.00
7 1.10 1.08 .97 .83 .55 .29 .08
8 .37 .35 .29 .22 .12 .05 .02
9 .30 .29 .26 .21 .13 .06 .02
10 0.04 0.04 0.03 0.03 0.01 0.01 0.00
11 .00 .00 .00 .00 .00 .00 .00
D9S1867:
1 1.40 1.37 1.25 1.09 .74 .40 .12
2 1.65 1.60 1.40 1.15 .69 .31 .08
3 0.01 0.00 .00 .01 .01 .01 .00
4 .75 .72 .61 .48 .26 .10 .02
5 .43 .42 .37 .32 .20 .10 .03
6 0.05 0.05 0.04 0.03 0.02 0.01 0.00
7 1.10 1.08 .97 .83 .55 .28 .08
8 .51 .49 .41 .32 .17 .08 .03
9 .60 .58 .52 .43 .27 .13 .03
10 .50 .48 .42 .34 .20 .09 .02
11 .12 .12 .10 .08 .05 .02 .01
D9S1843:
1 1.40 1.37 1.25 1.09 .74 .40 .12
2 1.69 1.63 1.43 1.19 .74 .36 .11
3 0 01.16 0.51 0.27 0.09 0.02 0.00
4 .75 .72 .61 .48 .26 .10 .02
5 .73 .71 .62 .51 .31 .14 .03
6 .25 .24 .21 .17 .10 .05 .01
7 0 0.91 0.27 0.05 .07 .06 .02
8 .68 .65 .56 .45 .25 .12 .04
9 .60 .58 .52 .43 .27 .13 .03
10 .50 .48 .42 .34 .20 .09 .02
11 .12 .12 .09 .07 .03 .01 .00
NOTE.—GATA89a11 and D9S1843 are the closest markers ﬂanking the proximal boundary and the
distal boundary, respectively, of the critical region (ﬁg. 1). Familial LOD scores for D9S1867 are shown,
since it is located in the critical region and yields the highest two-point LOD score (7.01 at u Å .00) for
the markers analyzed (table 1).
In our study, it was known prior to the genome scan the high rate of heterozygosity for the markers studied
(table 3). Despite the consanguinity in family CHAC7,that families CHAC2, CHAC7, and CHAC8 were con-
sanguineous (ﬁg. 1); however, these families alone an extended region of homozygosity across the CHAC
critical region was not seen in affected individuals (ﬁg.would provide insufﬁcient power to conclude linkage
solely by use of homozygosity mapping in a genomewide 1). This could be due to the fact that the parents
(CHAC7 I-1 and CHAC7 I-2) were related through asearch. Interestingly, haplotype analysis of affected indi-
viduals (including isolated cases), for the region studied, distant marriage, making the HBD in the offspring more
difﬁcult to detect, given this density of polymorphichas provided strong evidence of consanguinity in family
CHAC4 and in a family from which an isolated case markers. Further analysis for HBD in the affected indi-
viduals from family CHAC7, with more closely spacedwas studied (table 3). Inferred HBD in these individuals
could be due to chance; however, this is unlikely given markers, may help to reduce the candidate region.
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Table 3
HBD in CHAC-Affected Individuals
HAPLOTYPE FORb
NO. OF AVERAGE
MARKERa CHAC2 IV-5c CHAC2 IV-7c CHAC4 II-5 CHAC8 IV-1c Isolated Case ALLELESd HETEROZYGOSITYd
D9S147e 3 3 4 3 6 6 2 1 2 2 7 . . .
D9S15 6 6 2 6 2 2 5 3 2 5 7 . . .
D9S175 11 11 6 11 5 5 4 4 3 13 13 84
D9S1860 6 6 5 6 5 5 4 4 6 6 7 50
GATA89a11 1 1 2 1 2 2 3 3 3 3 4 . . .
GATA89c08 5 5 5 5 4 4 2 2 4 4 6 . . .
D9S1674 6 6 6 6 8 8 9 9 8 8 11 73
D9S153 2 2 2 2 2 2 5 5 5 5 6 76
D9S1780 4 4 4 4 5 5 2 2 3 3 9 71
D9S1867 2 2 2 2 6 6 2 2 6 6 8 82
GATA21f05 2 4 2 4 3 3 1 1 2 2 10 . . .
D9S1843 8 8 8 8 3 3 5 5 8 8 5 80
GATA3d04 5 4 5 4 4 5 1 1 4 4 7 . . .
D9S167 4 3 4 3 3 2 3 3 . . . 8 87
D9S152 3 4 3 4 3 6 3 3 7 7 9 83
a The polymorphic marker loci that are nonrecombinant with the CHAC locus (ﬁg. 1 and table 1) are underlined. For individuals CHAC2
IV-5 and CHAC2 IV-7, the region that reduces the critical region to exclude GATA21f05 lies between GATA89c08 and D931867.
b Contiguous regions of homozygosity that overlap with the CHAC disease interval (ﬁg. 1 and table 1) are indicated by shading.
c Offspring from a known consanguineous marriage.
d Determined across all CHAC families (Dib et al. 1996).
Autosomal dominant familial dilated cardiomyopathy contribute to the much-needed understanding of the
pathophysiology involved in basal ganglia degeneration(FDC) was mapped recently to chromosome 9q13-q22
in the interval between D9S153 and D9S152 (Krajinovic and in chorea. Given the similarities of Huntington dis-
ease, McLeod syndrome, and CHAC, at the clinical andet al. 1995), which overlaps with the CHAC critical
region (ﬁg. 2). Krajinovic et al. cite two genes as candi- the neuropathological levels, it appears quite likely that
these three choreatic syndromes share a common ﬁnaldates for the FDC gene, which also are attractive candi-
dates for the CHAC gene: The gene for Friedreich ataxia pathogenetic pathway, resulting, for example, from the
accumulation of neurotoxic amino acids in striatal neu-(9q13-q21.1) (Carvajal et al. 1996), a severe neurode-
generative disease with autosomal recessive transmission rons (Lipton and Rosenberg 1994). Elucidation of the
mechanism may help to design effective therapies forand heart involvement, is a good candidate, but recom-
bination events in families CHAC2, CHAC4, and these as yet untreatable disorders.
CHAC6 exclude D9S15 (table 2 and ﬁg. 1), a marker
tightly linked to FRDA (Fujita et al. 1990). Another Acknowledgments
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